Persister state-directed transitioning and vulnerability in melanoma
2022 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Persister state-directed transitioning and vulnerability in melanoma
Chauvistré, H.; Shannan, B.; Daignault-Mill, S. M.; Ju, R. J.; Picard, D.; Egetemaier, S. & Váraljai, R. et al. (2022)
Nature Communications, 13(1). DOI: https://doi.org/10.1038/s41467-022-30641-9
Documents & Media
Details
- Authors
- Chauvistré, Heike; Shannan, Batool; Daignault-Mill, Sheena M.; Ju, Robert J.; Picard, Daniel; Egetemaier, Stefanie; Váraljai, Renáta; Gibhardt, Christine S.; Sechi, Antonio; Kaschani, Farnusch; Roesch, Alexander
- Abstract
- Abstract Melanoma is a highly plastic tumor characterized by dynamic interconversion of different cell identities depending on the biological context. Melanoma cells with high expression of the H3K4 demethylase KDM5B (JARID1B) rest in a slow-cycling, yet reversible persister state. Over time, KDM5B high cells can promote rapid tumor repopulation with equilibrated KDM5B expression heterogeneity. The cellular identity of KDM5B high persister cells has not been studied so far, missing an important cell state-directed treatment opportunity in melanoma. Here, we have established a doxycycline-titratable system for genetic induction of permanent intratumor expression of KDM5B and screened for chemical agents that phenocopy this effect. Transcriptional profiling and cell functional assays confirmed that the dihydropyridine 2-phenoxyethyl 4-(2-fluorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexa-hydro-quinoline-3-carboxylate (termed Cpd1) supports high KDM5B expression and directs melanoma cells towards differentiation along the melanocytic lineage and to cell cycle-arrest. The high KDM5B state additionally prevents cell proliferation through negative regulation of cytokinetic abscission. Moreover, treatment with Cpd1 promoted the expression of the melanocyte-specific tyrosinase gene specifically sensitizing melanoma cells for the tyrosinase-processed antifolate prodrug 3-O-(3,4,5-trimethoxybenzoyl)-(–)-epicatechin (TMECG). In summary, our study provides proof-of-concept for a dual hit strategy in melanoma, in which persister state-directed transitioning limits tumor plasticity and primes melanoma cells towards lineage-specific elimination.
- Issue Date
- 2022
- Journal
- Nature Communications
- eISSN
- 2041-1723
- Language
- English
- Sponsor
- Deutsche Forschungsgemeinschaft https://doi.org/10.13039/501100001659
Foundation for the National Institutes of Health https://doi.org/10.13039/100000009
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation https://doi.org/10.13039/100005984
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329